TY - JOUR
T1 - Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo
AU - Pi, Rongbiao
AU - Mao, Xuexuan
AU - Chao, Xiaojuan
AU - Cheng, Zhiyi
AU - Liu, Mengfei
AU - Duan, Xiaolu
AU - Ye, Mingzhong
AU - Chen, Xiaohong
AU - Mei, Zhengrong
AU - Liu, Peiqing
AU - Li, Wenming
AU - Han, Yifan
PY - 2012/2/23
Y1 - 2012/2/23
N2 - We have previously synthesized a series of hybrid compounds by linking ferulic acid to tacrine as multifunctional agents based on the hypotheses that Alzheimer's disease (AD) generates cholinergic deficiency and oxidative stress. Interestingly, we found that they may have potential pharmacological activities for treating AD. Here we report for the first time that tacrine-6-ferulic acid (T6FA), one of these compounds, can prevent amyloid-β peptide (Aβ)-induced AD-associated pathological changes in vitro and in vivo. Our results showed that T6FA significantly inhibited auto- and acetylcholinesterase (AChE)-induced aggregation of Aβ 1-40 in vitro and blocked the cell death induced by Aβ 1-40 in PC12 cells. In an AD mouse model by the intracerebroventricular injection of Aβ 1-40, T6FA significantly improved the cognitive ability along with increasing choline acetyltransferase and superoxide dismutase activity, decreasing AChE activity and malondialdehyde level. Based on our findings, we conclude that T6FA may be a promising multifunctional drug candidate for AD.
AB - We have previously synthesized a series of hybrid compounds by linking ferulic acid to tacrine as multifunctional agents based on the hypotheses that Alzheimer's disease (AD) generates cholinergic deficiency and oxidative stress. Interestingly, we found that they may have potential pharmacological activities for treating AD. Here we report for the first time that tacrine-6-ferulic acid (T6FA), one of these compounds, can prevent amyloid-β peptide (Aβ)-induced AD-associated pathological changes in vitro and in vivo. Our results showed that T6FA significantly inhibited auto- and acetylcholinesterase (AChE)-induced aggregation of Aβ 1-40 in vitro and blocked the cell death induced by Aβ 1-40 in PC12 cells. In an AD mouse model by the intracerebroventricular injection of Aβ 1-40, T6FA significantly improved the cognitive ability along with increasing choline acetyltransferase and superoxide dismutase activity, decreasing AChE activity and malondialdehyde level. Based on our findings, we conclude that T6FA may be a promising multifunctional drug candidate for AD.
UR - http://www.scopus.com/inward/record.url?scp=84863144997&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0031921
DO - 10.1371/journal.pone.0031921
M3 - Journal article
C2 - 22384101
SN - 1932-6203
VL - 7
JO - PLoS ONE
JF - PLoS ONE
IS - 2
M1 - e31921
ER -